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ThispaperreviewstheevidencesupportingtheuseofetiologicaltreatmentforChagasdiseasethathaschangedthestandardofcare
for patients with Trypanosoma cruzi infection in the last decades. Implications of this evidence on diﬀerent levels of prevention
as well as gaps in current knowledge are also discussed. In this regard, etiological treatment has shown to be beneﬁcial as an
intervention for secondary prevention to successfully cure the infection or to delay, reduce, or prevent the progression to disease,
and as primary disease prevention by breaking the chain of transmission. Timely diagnosis during initial stages would allow for
the prescription of appropriate therapies mainly in the primary health care system thus improving chances for a better quality of
life. Based on current evidence, etiological treatment has to be considered as an essential public health strategy useful to reduce
disease burden and to eliminate Chagas disease altogether.
1.Introduction
One hundred years after Carlos Chagas identiﬁed and
described the Trypanosoma cruzi (T. cruzi) infection, there
are still millions of infected people and thousands of
newly diagnosed cases each year with Chagas disease (CD).
The scientiﬁc community has intermittently increased the
knowledge and understanding of how to manage patients
with acute and chronic CD [1]. Nonetheless, much more
research is still needed in order to improve care and answer
many unknown questions regarding this debilitating and
widespread disease, which has been estimated to aﬀect about
8millionchronicallyinfectedpeoplejustintheAmericas[2].
The goal of etiological treatment against Chagas disease
is to eliminate the parasite (T. cruzi) from the infected
individual, to decrease the probability of developing clinical
manifestationsofthedisease(e.g.,cardiovascularordigestive
diseases), and to break the chain of disease transmission [3].
Currently, there is a new scenario regarding the rec-
ommended etiological treatment against T. cruzi infection.
It is based on several strong evidences supported by basic
research, clinical trials, observational studies, and expert
opinions. In this paper, we review the current evidence
supporting etiological Chagas disease therapy organized
according to diﬀerent levels of prevention. Additionally, we
discuss the tools available to demonstrate cure in these
patients, and the need for further research required to
improve care for T. cruzi infected people.
2.MaterialsandMethods
We reviewed the evidence supporting the use of anti-T.
cruzi pharmacotherapy (etiological treatment) in order to
reduce or avoid the morbidity and mortality of Chagas
disease applied on diﬀerent levels of prevention. In this
regard, a MEDLINE search was conducted from January to2 Journal of Tropical Medicine
July 2011, using the term “Chagas disease” with the sub-
headings “diagnosis,” “prognosis,” “treatment,” drug names
(nifurtimox, benznidazole, and other drugs), “clinical trials,”
and “observational studies.” No restrictions regarding year,
language or country of publication were applied. Recent
guidelines as well as ongoing and unpublished studies were
also identiﬁed by consulting researchers and experts in
the ﬁeld. Evidence was organized according to the levels
of prevention addressed by the retrieved guidelines or
epidemiological researches. Finally, we reviewed the strength
of evidence for each indication in each level of prevention.
2.1. Deﬁnitions
2.1.1. Levels of Prevention. L e a v e l la n dC l a r k ’ sh a v ed e ﬁ n e d
three diﬀerent levels of prevention in human health (pri-
mary, secondary, and tertiary) in a classical textbook pub-
lished in 1953 [4]. Each of them includes diﬀerent means of
intervention according to the natural history of the disease.
Primary Prevention. These strategies intend to avoid the
disease’s development, including the acquisition of new
infection. Most population-based health promotion activi-
ties are primary preventive measures.
Secondary Prevention. These strategies attempt to diagnose
and treat an existing disease in its early stages before it results
in signiﬁcant morbidity.
Tertiary Prevention. These treatments aim to reduce the
negative impact of established disease by restoring function
and reducing disease-related complications.
In the last decades, Jamoulle has proposed a fourth
concept(quaternaryprevention), whichwasincorporated by
the WONCA International Classiﬁcation Committee [5]. In
this regard, quaternary prevention describes the set of health
activities aimed to mitigate or avoid the consequences of
unnecessary or excessive interventions in the health system.
Strength of recommendations as well as the quality level
of the evidence supporting these recommendations were
addressed according to the Quality Standards Subcommittee
or the Clinical Aﬀairs Committee of the Infectious Diseases
Society of America (IDSA) [6].
2.2. Strength of the Recommendation.
(A) Both strong evidence for eﬃcacy and substantial
clinical beneﬁt support recommendation for use. It
should always be oﬀered.
(B) Moderate evidence for eﬃcacy—or strong evidence
for eﬃcacy but only limited clinical beneﬁt—support
recommendation for use. It should generally be
oﬀered.
(C) Evidence for eﬃcacy is insuﬃcient to support a
recommendation for or against use. Or evidence for
eﬃcacy might not outweigh adverse consequences
(e.g., drug toxicity, drug interactions) or cost of the
treatment under consideration: optional.
( D )M o d e r a t ee v i d e n c ef o rl a c ko fe ﬃcacy or for adverse
outcome supports a recommendation against use. It
should generally not be oﬀered.
(E) Good evidence for lack of eﬃcacy or for adverse
outcome supports a recommendation against use. It
should never be oﬀered.
2.3. Quality of Evidence Supporting the Recommendation.
Type I: evidence from at least one properly designed ran-
domized, controlled trial.
Type II: evidence from at least one well-designed clinical
trial without randomization, from cohort or case-
controlled analytic studies (preferably from more
than one center), or from multiple time-series stud-
ies, or dramatic results from uncontrolled experi-
ments.
Type III: evidence from opinions of respected authorities
based on clinical experience, descriptive studies, or
reports of expert committees.
3. Results
3.1. Recommendations of Therapy and Strength of Evidence.
Several papers and guidelines have been published in the
last years [7–40], supporting with diﬀerent levels of strength
t h a te t i o l o g i c a lt r e a t m e n ti sa ne ﬀective intervention on
both the individual and public health. These studies reached
levels of evidence ranged from I to III, providing strength of
recommendations (A), (B), and (C) (see Table 1). We discuss
this criteria applied in diﬀerent scenarios as follows.
3.1.1. Eﬃcacy of Treatment during Acute Phase of Infection.
Several studies have shown the beneﬁt of treatment during
acute phase with both benznidazole and nifurtimox with
al e v e lo fe v i d e n c eT y p eIo rI I[ 10–15]. The assessment
of failure and/or eﬃcacy of treatment on patients treated
during acute phase is demonstrable in short time because
the parasitemia, whether direct or not (parasitological test or
molecular test), becomes negative a few days after the end
of treatment. In addition, antibodies disappear completely
(seronegativization) in at least 65% of cases, with some
studies demonstrating seronegativity in 100% of cases up
to 18 months of follow up after treatment. This eﬀect is
independent of the age of the patients, including newborns
(congenital transmission), children, and adults. The absence
ofparasitemiademonstratedbydirectmethodsuchusStrout
or micromethod always precedes the reduction of antibodies
[10–15].
In general, treatment is well tolerated during the acute
phase, and the risk of potential adverse events is counterbal-
anced by the reduction of clinical manifestations of the acute
phase of Chagas infection, and even the associated risk of
death. There is wide consensus that all patients undergoing
the acute phase of infection or reactivation of chronic
infection must be treated (strength of recommendation (A)).Journal of Tropical Medicine 3
Table 1: Indication of treatment against Trypanosoma cruzi infection based on diﬀerent levels of quality of evidences and tools to assess
eﬃcacy or failure.
Indication (strength of the
recommendation, and level of evidence) Drug Eﬃcacy† Time elapsed Failure‡ Comments
Acute phase:
vector transmission ((A) I) [10]
Congenital transmission ((A) II) [11–15]
Bz, Nftx 65–100% 8m o n t h so r
more 5%
Medium term of followup to asses
eﬃcacy
Good tolerance
Early chronic phase (children) ((A) I)
[16–22] Bz 50–70% 3–15 years 5%
Most of the cases were children under
12 yo.
Long term of followup to asses eﬃcacy
Good tolerance
Diﬀerent response for T. cruzi lineage I
and II
Some resistant clones were observed
Late chronic phase (adults,
indeterminate, cardiac/digestive/other
diseases) ((B) II; (C) II) [7, 18, 23–31]
Bz, Nftx 30% >20 years 10%
Long term of followup
Frequent side eﬀects
Eﬃcacy to prevent evolution is under
research
Moderate-bad tolerance
Diﬀerent response for T. cruzi lineage I
and II
Some resistant clones were observed
Pregnant ((E) III) [32, 33]N A N A N A N A
Some accidental or necessary
treatment during pregnant with acute
phase did not show damaging eﬀect in
the child
Treatment of pregnant women is
currently not recommended [7, 9]
Immunocompromised (i.e., HIV,
Transplant, other) ((A) II) [34–40] Bz, Nftx ND ND <5%
Etiological treatment aborts severe
forms of reactivation as
meningoencephalitis, myocarditis,
panniculitis, and so forth,
Good response
No evidence about prophylaxis. Under
research
A c c i d e n t s( ( B )I I I )[ 33] Bz, Nftx NA NA NA 10–15 days treatment immediately
after accidents avoid infection
†Maximum rate of seronegativization.
‡Maximum rate of positive parasitologic test after treatment.
Bz: benznidazole, NA: not applicable, ND: no data, Nftx: nifurtimox.
3.1.2. Eﬃcacy of Treatment during Chronic Phase of Infection.
Several studies (evidence Type I) have provided support
to the use of etiological treatment (benznidazole) during
early stages of chronic infection in children [16–22]. Two
studies have shown eﬃcacy in this population through
double blinded placebo-controlled trials of benznidazole
for children aged 6 to 12 years old with asymptomatic T.
cruzi infection demonstrated approximately 60% eﬃcacy, as
assessed by conversion from positive to negative serology
r e s u l t s3t o4y e a r sa f t e rt r e a t m e n t[ 16, 17]. Rates of
seronegativization up to 70% were established with etio-
logical treatment after long-term follow-up (15 years) in
South America, and up to 50% after short-term followup (3
years) in Central America. Furthermore, additional studies
(evidence Type II) have shown that seronegativization with
etiological treatment is also possible in later stages of the
chronic infections in adults [7, 18, 23–31]. However, rate of
seronegativizationofantibodies(serologicaltest)seemstobe
directly related to the age of patients. Although a complete
seronegativization can be obtained in more than 70% of the
cases in children, the seronegativization rate have reached
about 30% in adult patients after a long-term followup,
around 20 years [7, 16–31].
Fall in antibodies titers after treatment in children is
faster than in adults, even if it does not cross the cutoﬀ
to become nonreactive. The decrease in antibody titers is
signiﬁcant during the early months following treatment.
A statistically signiﬁcant reduction is visible at 3 months
with EIA and IFA, and at 6 months with IHA [16, 17].
This phenomena was also observed in adult patients [26].
Young children with longer-term followup have higher rates
of seronegativization after treatment as compared to child
patients with short-term followup, and equal phenomena
occurs among adult patients with long-term followup in
comparison with adult patients with short followup [9].
Assessment of etiological treatment eﬀect is another
important issue under research on Chagas disease. Demon-
stration of antiparasitic eﬀects after treatment can be4 Journal of Tropical Medicine
performed by the detection of antibodies, parasites, and/or
parasite DNA. The success of the treatment is determined by
the disappearance of antibodies using serological tests, while
therapeutic failure only can be demonstrated by showing the
persistence of the parasite using parasitological methods.
The assessment of failure of treatment on patients
treated during the chronic phase could be demonstrable in
short time because the parasitemia (when it is present by
parasitological test or molecular test) disappears at the end
of treatment if treatment is successful. When failure occurs,
evidenceofparasitemiaremainspositive aftertreatment(not
more than 5% in children or 10% in adults) [9, 10, 17,
18, 20, 41, 42]. However, Gallerano and Sosa [43] showed
a higher rate of xeno positives including treatment with
nifurtimox, benznidazole, and allopurinol. Though, this last
drug (allopurinol) did not show consistent results when they
were tested in clinical trials [44, 45].
Other methodologies to evaluate the eﬀectiveness of
antiparasitic treatments have been tested, but have not
reached consensus to change current testing strategy [9].
Methodstodetecttheparasite’sgenomicfragmentsintissues
and body ﬂuids using polymerase chain reaction (PCR)
have proved to be promising tools for the assessment of
therapy [13, 36, 45–49], and it was recently standardized
for diagnosis [50]. Projects for standardization of PCR for
assessing therapy which look for the presence of parasites in
the blood are underway. There is agreement that, even with
limitation, it will be a useful tool to improve the assessment
of treatment failure.
Regarding assessment of treatment eﬃcacy, several
researchers are looking for solutions. Molecular methods are
showing attributes for making a timely diagnosis at birth
[11, 13, 51].
Since tolerance to etiological treatment in children is
better than that in adults (see Section 3.3), there is a general
agreement that children and adolescents undergoing chronic
Chagas phase have to be treated (strength of recommenda-
tion (A)). On the other hand, the rate of seronegativization
in adult patients (about 30%) based on evidence from
observational studies linking the seronegativization to the
prevention of clinical disease is currently under research
[7, 18, 23–31]. Furthermore, higher rates of adverse events
(with a 17% of abandon rate) are seen in adult patients
in comparison with children, making this recommendation
weaker in adults (strength of recommendation (B)).
In the case of adult patients undergoing the chronic
phase of infection, treatment could be oﬀered to them after
carefully addressing possible beneﬁts and adverse events. If
accepted, therapy should be prescribed due to the strength of
evidence available today.
3.1.3. Eﬃcacy of Treatment in Special Cases. Evidence Type
III supports that health workers, researchers, and so forth
who suﬀer accidents with infected blood have to be treated
under speciﬁc protocols [33]. Regarding immunocompro-
mised patients, available studies (evidence Type II) have
shown that after etiological treatment, patients recover from
severe manifestations of reactivation such as meningoen-
cephalitis, myocarditis, and panniculitis [36, 52]. However,
in these cases the main objective is recovery from life-
threatening acute events rather than seronegativization, due
to the limited ability to interpret serological test results
in states of immunosuppression. Since the severity of
reactivation and the risk of death are associated, there is
a general agreement that these patients must be treated
(strength of recommendation (A)). On the other hand, no
current evidence supports the use of etiological treatment as
prophylaxis in immunocompromised patients with chronic
chagasic infection without evidence of reactivation.
Although some studies have reported the etiologic treat-
ment of pregnant women without adverse eﬀects in the new
born [32, 33], treatment using benznidazole or nifurtimox is
currently not recommended for pregnant women (absolute
contraindication) [7, 9]. Additional contraindications to use
of etiological treatment include patients undergoing severe
acute or chronic liver or kidney disease not related to T. cruzi
infection (relative contraindication), and lactation (relative
contraindication) [7, 9].
Table 1 shows a summary of diﬀerent scenarios for
etiologic treatment against T. cruzi infection, and results of
diﬀerent ways for assessing therapeutic response.
3.2. Tolerance and Adherence. During treatment, patients
must be under continuous medical supervision. Based on
prior experiences, treatment tolerance is good and patients
have not denoted serious side eﬀects [8, 19, 27, 41, 53, 54].
Although cases with severe side eﬀects have been reported,
they have generally been associated with diﬃculties in
seeking timely medical attention or receiving adequate care.
Side eﬀects are more frequently observed in adolescents
and adults than in children and babies. In neonates and in
children up to 4 years old, tolerance is excellent. In all cases,
side eﬀects disappeared when the dose was decreased or the
treatment suspended. Types of side eﬀects seen and their
distribution during treatment are shown in Figure 1.
Other types of side eﬀects include reversible clastogenesis
and mutagenesis with benznidazole and nifurtimox without
any associated manifestations [55, 56], toxicity against other
tissues [57] or increased risk of lymphomas in experimental
animals [58] have been described, but never demonstrated
among a general population of infected patients undergoing
treatment[59]andneverplayedaroleinanimalmodels[60].
Adequatemanagementofsideeﬀectsisnecessarytocarryout
treatmentaswellastodiminishunfoundedfearswiththeuse
of trypanocidal drugs [53, 61].
3.3. Role of Etiological Treatment against T. cruzi Infection on
SeveralLevelsofPreventioninPublicHealth. Therecommen-
dations of etiological treatment allow for action on several
levels of public health prevention.
Retrievedstudiesprovideevidenceforapplyingstrategies
of health care to control programs in several countries,
whereby a greater portion of the population could get
diagnosis, treatment, and cure, generating a new scenario for
the reduction in disease burden in the future.
3.3.1. Primary Prevention Level. If the goal is to avoid the
acquisition of a new infection, etiological treatment couldJournal of Tropical Medicine 5
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Figure 1: Timeline of side eﬀects of benznidazole and nifurtimox.
have an indirect eﬀect when children and young people are
treated. Curing children and women in reproductive age
would avoid future events of congenital T. cruzi transmission
in newborns [62] (recommendation (B), and evidence Type
III). In addition, the availability of potential blood and
organ donors will be increased by treating those infected.
Unfortunately, eﬀectiveness of etiological treatment for these
primary prevention indications remains unknown, although
it can be assumed to be at least equal to seronegativization
rates observed in available studies. Another strategy would
be the development of a treatment that can be administered
to pregnant women, such as is used for HIV infection, to
avoid congenital transmission during pregnancy. However,
safetyinformationonthesedrugswouldbenecessaryforthis
strategy, and this is not currently available.
Etiological treatment in case of accidents with material
contaminated with parasites or blood samples of patients
infected with T. cruzi could also be considered as an
indication for primary prevention. Actually, the treatment is
not strictly a prophylaxis because it is not possible to avoid
the infections, but the infection can be aborted immediately
after accidents with a timely treatment to get an appropriate
concentration of speciﬁc drugs (recommendation (B), and
evidence III) [33].
3.3.2. Secondary Prevention Level. If prevention activities
cannot avoid infection in children, the cure of infected chil-
dren is still possible by prescribing etiological treatment [10–
22]. In this regard, etiological treatment is indicated when
damages from cardiac or digestive disease are not strongly
present in these children. This is the best opportunity to get
seronegatization and avoid disease, thus preserving social,
mental, and physical health into adulthood [63, 64].
A national control program has been incorporated
progressively in several Latin-American countries. It has
consisted of the screening of child populations as a regular
strategy to oﬀer opportunities for diagnosis and treatment
(recommendation (A), and evidence Type I) [65], as well
as timely diagnosis and treatment of children born with
congenital infection (recommendation (A), and evidence
Type II). The positive eﬀect of curing children detected by
serological screening must be assessed by taking into account
patterns of disease transmission, evolution, and a calculation
of the burden of disease attributable to Chagas disease, in
order to analyze the usefulness of serology as an indicator of
the action against the vector.
Other indication for etiological treatment in secondary
prevention is to avoid reactivation of a chronic infection.
Immunosuppression due to immunosuppressive therapies
[36] or HIV/AIDS [52] increases the risk of reactivation in
patients with chronic infection. Although the eﬀectiveness
of etiological treatment for the clinical control of episodes
of reactivation has been proven, it is necessary to gather
evidence as to whether preventive treatment is eﬀective
in patients with no signs of clinical reactivation and with
abnormal immunological parameters [66]. In this regard,
some protocols recommend the treatment of organ donors
infected with T. cruzi in order to reduce risk of transmission
by transplant [67]. In this case, the treatment should be
considered an act of primary prevention (recommendation
(A), and evidence Type II).
3.3.3. Tertiary Prevention Level. The use of etiological treat-
ment against T. cruzi infection in order to reduce the
negative impact of established disease is under evaluation
through two randomized clinical trials, which assess the
eﬃcacy in patients with cardiac disease [68–70]. These trials
are appraising the eﬃcacy of benznidazole for preventing
progression of cardiac disease.
Several observational studies have been published show-
ing eﬀects of etiological treatment in patients infected
with T. cruzi, on prevention of the progression of chronic
chagasic cardiomyopathy [18, 27, 41, 43, 71]. These studies
reached quality of evidence Type II, providing strength of
recommendation(B)and(C).Theprognosisofpatientswith
heartfailureoradvancedstagesofChagas’cardiomyopathyis6 Journal of Tropical Medicine
poor [72], but similar to others that develop heart failure for
other reasons. Since the disease is chronic and heart damage
develops over decades, it is very important to recognize
factors that are determinant of disease progression in the
early stages [73]. Etiological treatment should be considered
as a protective factor in the model of physiopathology of
Chagas’ cardiomyopathy.
As mentioned above, the eﬀectiveness of etiological
treatment for the control of episodes of reactivation has
been proven, showing recovery of severe manifestations of
reactivation such as meningoencephalitis, myocarditis, and
panniculitis [36, 52].
4. Discussion
Recommendations for appropriate care of patients are
increasing, putting emphasis on the care of patients in
the primary health care system, the use of other levels
of care when necessary [74–76], and the incorporation of
psychological aspects into care [63, 64]. In this context,
it is important to consider the available evidence about
etiological treatment, and to maintain the perspective of
etiological treatment as a public health tool in multiple levels
of prevention, along with other interventions available for
Chagas disease control and treatment.
In Chagas disease, the best examples of primary preven-
tion are vectorial control (based on surveillance) and control
of blood and organ donors. However, etiological treatment
has an important role in primary prevention and has to be
considered a key element on among other strategies of the
Chagas disease control programs.
The best example of secondary prevention in Chagas
disease is the control of congenital transmission, and the
diagnosis of infection in children (deﬁned as chronic recent
infection) or young-adult patients in chronic phase without
clinical manifestations (sign and/or symptom) [77].
Use of etiological treatment for tertiary prevention in
Chagas disease is currently supported by recommendation
levels (B) and (C), when given in addition to complementary
therapies in patients with cardiac disease to reduce the
clinical progression of the disease. For instance, cardiac
transplant is a procedure that has been applied and has
demonstrated clinical beneﬁt in some patients with terminal
heart failure [78]. Stem cell transplant is a new therapy
applied to produce cardiac regeneration through distinction
or increase heart myocytes or neovascular proliferation in
patients in the ﬁnal stage of congestive heart failure [79–81],
but the results are still insuﬃcient on Chagas disease, and
there is no consensus about its eﬃcacy [80].
Regarding quaternary prevention, a national policy of
etiologicaltreatmentofinfectedpeopleshouldbeconsidered
as an activity. This approach has been utilized by several
Latin-American countries in the last decades.
The assessment of eﬀect of treatment against T. cruzi
infection requires a clear understanding about the combina-
tion of variables to an appropriate interpretation of results
to appraise. Among others, the main variables are the tools
usedasindicators(parasitological,molecular,andserological
tests), the phase of infection (acute or chronic) that the
patient is undergoing when he/she was treated, and the time
elapsed between treatment and the application of the test to
assess eﬃcacy/failure.
The ideal assessment of response to speciﬁc treatment
is the detection of free parasites in the patient’s blood [82]
or tissues [83], which permits clear observation of failure of
treatment.
Only limited methods are available for assessing the
eﬃcacy of treatment. It is also necessary to validate new tools
to conﬁrm cure or failure in a timely manner after a full
course of treatment has been given during the chronic phase,
and studies are ongoing to validate PCR and standardized
and validate qPCR.
If persistence of the parasite is identiﬁed, after verifying
if the drug was taken correctly, it is necessary to consider the
possibility that the parasite has developed resistance [84, 85].
Possible regional diﬀerences (host, T. cruzi strain, etc.), have
also been described [10, 22], but more observation is needed
to conﬁrm this hypothesis.
After etiologic treatment, even in cured patients, the
antibodies may remain detectable in sera for a long term
(for years) until they become negative. Because of this
phenomenon, it would be necessary to delve into the clinical
history of patients with reactive serology, asking the question
“did he/she receive treatment in the past?” When given an
aﬃrmative answer, the serological test has a limited value,
because we must consider whether this reactivity is reﬂecting
an active infection or if the patient was cured and he/she is
becoming negative.
Current recommendations have put the bulk of the
diagnostic and treatment responsibility on the primary
health care system. Yet the management of infected patients
has some basic limitations, but several researches are looking
for solutions.
(a) Current drugs are able to cure infection (or prevent
disease) in adult patients during the chronic phase, which is
when the ﬁrst contact is made with most infected patients,
and clinical trials are ﬁnishing or ongoing to demonstrate
eﬀectsof conventional treatmenton this population [69,70].
(b) New pediatric presentation of benznidazole is under
evaluation to eliminate infection in newborns, and children
with recent chronic infection [86]. Most new cases are, in
fact, newborns with congenital infection.
Overall, the priorities in Chagas disease research should
be to produce new drugs providing a shorter treatment
course with fewer side eﬀects, and to devise pediatric
formulas. Some strategies, such as testing old drugs for
extending current prescriptions, screening new compounds,
testing drugs developed for other prescription such as
pozanonzole, or developing new compounds are being used
(Clinical Trial for the Treatment of Chronic Chagas Disease
with Posaconazole and Benznidazole; NCT01162967) [69,
86]. Associations of compounds with diﬀerent mechanisms
of action have been mentioned as another way to look for
new treatment alternatives [87].
Based on current disease understanding during chronic
phase of infection, there is consensus that every patient
infected with T. cruzi must be (children) or should be
treated (adults). Treatment can cure infection and reduceJournal of Tropical Medicine 7
or prevent the progression to the Chagas-related heart
disease/cardiomyopathy. The current evidence of beneﬁts
and limitations of etiological treatment, based on clinical
and implementation research, serve to prioritize strategies in
primary health care, focusing on completing the scheme of
treatment, rather than demonstrating serological negativiza-
tion.
To incorporate etiological treatment as a public health
strategy which is useful at the primary, secondary, and
tertiarypreventionisessentialtoreduceburdenofthedisease
and to eliminate Chagas disease as a public health issue.
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